Blog Archives
Plasma Amyloid-beta Biomarker Associated with Cognitive Decline in Preclinical Alzheimer’s Disease
Lim YY, Maruff P, Kaneko N, Doecke J, Fowler C, Villemagne VL, Kato T, Rowe CC, Arahata Y, Iwamoto S, Ito K, Tanaka K, Yanagisawa K, Masters CL, Nakamura A (2020).
Total Aβ(42)/Aβ(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
Doecke JD, Pérez-Grijalba V, Fandos N, Fowler C, Villemagne VL, Masters CL, Pesini P, Sarasa M (2020).
Longitudinal evaluation of the natural history of amyloid-β in plasma and brain
Burnham SC, Fandos N, Fowler C, Pérez-Grijalba V, Dore V, Doecke JD, Shishegar R, Cox T, Fripp J, Rowe C, Sarasa M, Masters CL, Pesini P, Villemagne VL (2020).
Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimer’s Disease
Lim WLF, Huynh K, Chatterjee P, Martins I, Jayawardana KS, Giles C, Mellett NA, Laws SM, Bush AI, Rowe CC, Villemagne VL, Ames D, Drew BG, Masters CL, Meikle PJ, Martins RN (2020).
Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer’s disease
Dhiman K, Gupta VB, Villemagne VL, Eratne D, Graham PL, Fowler C, Bourgeat P, Li QX, Collins S, Bush AI, Rowe CC, Masters CL, Ames D, Hone E, Blennow K, Zetterberg H, Martins RN (2020).
Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
Doecke JD, Ward L, Burnham SC, Villemagne VL, Li QX, Collins S, Fowler CJ, Manuilova E, Widmann M, Rainey-Smith SR, Martins RN, Masters CL, AIBL (2020).
A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A (2019).
Klotho allele status is not associated with Abeta and APOE epsilon4-related cognitive decline in preclinical Alzheimer’s disease
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM (2019).
COMT val158met is not associated with Abeta-amyloid and APOE epsilon4 related cognitive decline in cognitively normal older adults
Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Sohrabi HR, Peretti M, Lim YY, Weinborn M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM (2019).
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K (2018).